A team from the Rockefeller University, New York, USA, studied the in vitro effect of three NO-NSAIDs on colonocyte kinetics. These were NO-aspirin, NO-sulindac, and NO-ibuprofen.
They assessed the potential role of these agents in colon cancer chemoprevention and reported their findings in Cancer Research.
|Nitric oxide-releasing NSAIDs reduce in vitro growth of colon cancer cells.
It was found that all three NO-NSAIDs reduced the growth of cultured HT-29 colon adenocarcinoma cells much more effectively than the corresponding NSAIDs.
This effect was due to the inhibition of proliferation and induction of apoptosis. It may also have been caused by the induction of novel cell changes, characterized by extensive DNA degradation.
NO-NSAIDs were additionally found to block the G0-G1 to S cell cycle transition.
Jennie Williams, of the American Health Foundation, Valhalla, and her team concluded, "The superior effectiveness and safety profile of NO-NSAIDS, compared with traditional NSAIDs, makes them promising candidates for chemopreventive agents against colon cancer."